Real Time Characterization of BA.2.86 and Its Variant (JN.1) in Senegal Using Midnight Protocol

Year : 2024 | Volume :01 | Issue : 02 | Page : 16-21
By

    Abdou Padane

  1. Marilyne Aza-Gnandji

  2. Seyni Ndiaye

  3. Marièma Sarr

  4. Cyrille Kouligueul Diedhiou

  5. Astou Gueye

  6. Yacine Amet Dia

  7. Aminata Mboup

  8. Abdoulaye Samba Diallo

  9. Ousmane Diop

  10. Ambroise Ahouidi

  11. Papa Alassane Diaw

  12. Souleymane Mboup

Abstract

During the week ending August 13th, 2023, the most prevalent variant of interest (VOI), uploaded to GISAID, was the BA.2.86 variant. This SARS-CoV-2 Omicron lineage was described as the first phylogenetically distinct from the currently circulating SARS-CoV-2 Omicron XBB lineages, including EG.5.1 and HK.3. Compared to the XBB and BA.2 lineages, the BA.2.86 possesses more than 30 mutations in the Spike (S) protein, suggesting a significant potential for immune evasion. The BA.2.86 variant evolved and its descendant, JN.1 (BA.2.86.1.1) appeared in late 2023 and is currently classified as the new variant of interest by the WHO. Here, we carried out the characterization of the BA.2.86 SNPs (the JN.1 variant), which we most identified in Senegal from samples collected during December 2023 and January 2024. Nine of the sequences of these JN.1 variants that we identified have been published and are available on GISAID (EPI_ISL_18783717 to EPI_ISL_18783733). Despite the great immune invasion capacity of this BA.2.86 variant and its JN.1 descendants, it is important to note that Spike protein is also targeted by existing vaccines and current vaccines should act against these VOI.

Keywords: SARS-CoV-2, Lineages, Omicron variant, BA.2.86.1.1, JN.1.

[This article belongs to International Journal of Vaccines(ijv)]

How to cite this article: Abdou Padane, Marilyne Aza-Gnandji, Seyni Ndiaye, Marièma Sarr, Cyrille Kouligueul Diedhiou, Astou Gueye, Yacine Amet Dia, Aminata Mboup, Abdoulaye Samba Diallo, Ousmane Diop, Ambroise Ahouidi, Papa Alassane Diaw, Souleymane Mboup.Real Time Characterization of BA.2.86 and Its Variant (JN.1) in Senegal Using Midnight Protocol.International Journal of Vaccines.2024; 01(02):16-21.
How to cite this URL: Abdou Padane, Marilyne Aza-Gnandji, Seyni Ndiaye, Marièma Sarr, Cyrille Kouligueul Diedhiou, Astou Gueye, Yacine Amet Dia, Aminata Mboup, Abdoulaye Samba Diallo, Ousmane Diop, Ambroise Ahouidi, Papa Alassane Diaw, Souleymane Mboup , Real Time Characterization of BA.2.86 and Its Variant (JN.1) in Senegal Using Midnight Protocol ijv 2024 {cited 2024 Mar 30};01:16-21. Available from: https://journals.stmjournals.com/ijv/article=2024/view=136852


References

  1. Padane A, Kanteh A, Leye N, Mboup A, Manneh J, Mbow M, Diaw PA, Ndiaye BP, Lo G, Lo CI, Ahoudi A. First detection of SARS-CoV-2 variant B. 1.1. 7 in Senegal. New microbes and new infections. 2021 May 1;41:100877.
  2. Diédhiou CK, Padane A, Gueye K, Ndiour S, Mboup A, Mbow M, Lo CI, Leye N, Ndoye AS, Ndiaye AJ, Diagne ND. Heterogeneity of the Omicron variant in Senegal. New Microbes and New Infections. 2022 Apr;47.
  3. Padane A, Diedhiou CK, Gueye K, Ndiour S, Diagne ND, Mboup A, Mbow M, Lo CI, Leye N, Ndoye AS, Ndiaye AJ. Dynamics of Variants of Concern (VOC) of SARS-CoV-2 during the Different Waves of COVID-19 in Senegal. COVID. 2022 May 30;2(6):691-702.
  4. Gueye K, Padane A, Diédhiou CK, Ndiour S, Diagne ND, Mboup A, Mbow M, Lo CI, Leye N, Ndoye AS, Ndiaye AJ. Evolution of SARS-CoV-2 Strains in Senegal: From a Wild Wuhan Strain to the Omicron Variant. COVID. 2022 Aug 9;2(8):1116-24.
  5. Padane A, Tegally H, Ramphal Y, Seyni N, Sarr M, Diop MM, Diedhiou CK, Mboup A, Diouf ND, Souaré A, Diagne ND. An emerging clade of Chikungunya West African genotype discovered in real-time during 2023 outbreak in Senegal. medRxiv. 2023 Nov 15.
  6. An Y, Zhou X, Tao L, Xie H, Li D, Wang R, Hu H, Xu Z, Dai L, Xu K, Gao GF. SARS-CoV-2 Omicron BA. 2.86: less neutralization evasion compared to XBB sub-variants. bioRxiv. 2023:2023-09.
  7. Franse CB, Rietjens JA, Burdorf A, van Grieken A, Korfage IJ, van der Heide A, Raso FM, van Beeck E, Raat H. A prospective study on the variation in falling and fall risk among community-dwelling older citizens in 12 European countries. BMJ open. 2017 Jun 1;7(6):e015827.
  8. Patil R, Uusi-Rasi K, Kannus P, Karinkanta S, Sievänen H. Concern about falling in older women with a history of falls: associations with health, functional ability, physical activity and quality of life. Gerontology. 2013 Oct 8;60(1):22-30.
  9. Delbaere K, Close JC, Brodaty H, Sachdev P, Lord SR. Determinants of disparities between perceived and physiological risk of falling among elderly people: cohort study. Bmj. 2010 Aug 19;341.
  10. Zhang L, Kempf A, Nehlmeier I, Cossmann A, Richter A, Bdeir N, Graichen L, Moldenhauer AS, Dopfer-Jablonka A, Stankov MV, Simon-Loriere E. SARS-CoV-2 BA. 2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell. 2024 Feb 1;187(3):596-608.
  11. Quarleri J, Delpino M, Galvan V. Anticipating the future of the COVID-19 pandemic: insights into the emergence of SARS-CoV-2 variant JN. 1 and its projected impact on older adults. GeroScience. 2024 Jan 10:1-5.
Regular Issue Subscription Original Research
Volume 01
Issue 02
Received February 27, 2024
Accepted March 21, 2024
Published March 30, 2024
Views: 51